IGF1R and familial pancreatic carcinoma: MK‐0646 or dalotuzumab, a humanized IgG1 monoclonal antibody which binds and blocks IGF1R (IGF1 receptor) (Atzori et al., 2011), is evaluated in combination with gemcitabine, or gemcitabine plus erlotinib, in patients with advanced pancreatic cancer to test its role in progression‐free and overall survival in correlation with the expression of IGFIR, AKT, and diverse EMT biomarkers (NCT00769483) (Table 1).